Publicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (5)

2022

  1. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

2021

  1. Small molecule-based enzyme inhibitors in the treatment of primary hyperoxalurias

    Journal of Personalized Medicine, Vol. 11, Núm. 2, pp. 1-31

2019

  1. Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene.

    Stem Cell Research, Vol. 41

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

2016

  1. Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation

    Stem Cell Research, Vol. 16, Núm. 1, pp. 116-119